Get started
Author

Anna Travesa

ORCID: 0009-0003-7572-1662
Observed ORCID: 0009-0003-7572-1662
OpenAlex ID: A5007911663
Nuclear transport factors: global regulation of mitosis
2015 · Douglass J Forbes, Anna Travesa, et al. · Current Opinion in Cell Biology · 129
DNA replication stress differentially regulates G1/S genes via Rad53‐dependent inactivation of Nrm1
2012 · Anna Travesa, Dwight Kuo, et al. · The EMBO Journal · 79
PDF
Distinct Phosphatases Mediate the Deactivation of the DNA Damage Checkpoint Kinase Rad53
2008 · Anna Travesa, Alba Duch, et al. · Journal of Biological Chemistry · 62
Repression of G 1 /S Transcription Is Mediated via Interaction of the GTB Motifs of Nrm1 and Whi5 with Swi6
2013 · Anna Travesa, Tatyana I. Kalashnikova, et al. · Molecular and Cellular Biology · 40
Analysis of the initiation of nuclear pore assembly by ectopically targeting nucleoporins to chromatin
2015 · Michal Schwartz, Anna Travesa, et al. · Nucleus · 37
PDF
Cyclin Regulation by the S Phase Checkpoint
2010 · Gloria Palou, Roger Palou, et al. · Journal of Biological Chemistry · 20
Reprint of “Nuclear transport factors: global regulation of mitosis”
2015 · Douglass J Forbes, Anna Travesa, et al. · Current Opinion in Cell Biology · 14
Exportins can inhibit major mitotic assembly events in vitro: membrane fusion, nuclear pore formation, and spindle assembly
2020 · Matthew S. Nord, Cyril Bernis, et al. · Nucleus · 11
Turned on by genotoxic stress
2012 · Anna Travesa, Curt Wittenberg · Cell Cycle · 7
449 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors
2022 · Brett Hall, Anna Travesa, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
377 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors
2026 · Amy E Axel, Amy Yamamura, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Table S4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Data from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 6 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 5 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Table 1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS - and RAF -Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al. · Cancer Research
Works count: 32
Citation count: 401
H-index: 8
I10-index: 8
Year
Topic
Type